Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023
- PMID: 38233610
- PMCID: PMC10917820
- DOI: 10.1007/s10096-024-04752-8
Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023
Abstract
Objectives: The occurrence of metallo-beta-lactamase-producing Pseudomonas aeruginosa (MBL-PA) isolates is increasing globally, including in Switzerland. The aim of this study was to characterise, phenotypically and genotypically, the MBL-PA isolates submitted to the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) reference laboratory over a 12-month period from July 2022 to July 2023.
Methods: Thirty-nine non-duplicate MBL-PA Isolates were submitted to NARA over the study period from across Switzerland. Susceptibility was determined by broth microdilution according to EUCAST methodology. Whole-genome sequencing was performed on 34 isolates. Sequence types (STs) and resistance genes were ascertained using the Centre for Genomic Epidemiology platform. MBL genes, blaNDM-1, blaIMP-1, and blaVIM-2, were cloned into vector pUCP24 and transformed into P. aeruginosa PA14.
Results: The most prevalent MBL types identified in this study were VIM (21/39; 53.8%) followed by NDM (11/39; 28.2%), IMP (6/39; 15.4%), and a single isolate produced both VIM and NDM enzymes. WGS identified 13 different STs types among the 39 isolates. They all exhibited resistance to cephalosporins, carbapenems, and the beta-lactam-beta-lactamase inhibitor combinations, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam, and 8 isolates were cefiderocol (FDC) resistant. Recombinant P. aeruginosa strains producing blaNDM-1, blaIMP-1, and blaVIM-2 exhibited FDC MICs of 16, 8, and 1 mg/L, respectively.
Conclusions: This study showed that the MBL-PA in Switzerland could be attributed to the wide dissemination of high-risk clones that accounted for most isolates in this study. Although FDC resistance was only found in 8 isolates, MBL carriage was shown to be a major contributor to this phenotype.
Keywords: Pseudomonas aeruginosa; Carbapenems; Epidemiology; Metallo-beta-lactamase.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022.Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):571-585. doi: 10.1007/s10096-024-04994-6. Epub 2024 Dec 20. Eur J Clin Microbiol Infect Dis. 2025. PMID: 39704920 Free PMC article.
-
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.Microbiol Spectr. 2024 Apr 2;12(4):e0383623. doi: 10.1128/spectrum.03836-23. Epub 2024 Mar 14. Microbiol Spectr. 2024. PMID: 38483164 Free PMC article.
-
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0206721. doi: 10.1128/AAC.02067-21. Epub 2021 Dec 20. Antimicrob Agents Chemother. 2022. PMID: 34930034 Free PMC article.
-
Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.Microbiol Spectr. 2022 Oct 26;10(5):e0169722. doi: 10.1128/spectrum.01697-22. Epub 2022 Oct 3. Microbiol Spectr. 2022. PMID: 36190424 Free PMC article.
-
ML302, a Novel Beta-lactamase (BLA) Inhibitor.2012 Apr 16 [updated 2014 May 13]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. 2012 Apr 16 [updated 2014 May 13]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. PMID: 23762954 Free Books & Documents. Review.
Cited by
-
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40064744 Free PMC article. Review.
-
Multidrug-Resistant Bacteria in Surgical Intensive Care Units: Antibiotic Susceptibility and β-Lactamase Characterization.Pathogens. 2024 May 15;13(5):411. doi: 10.3390/pathogens13050411. Pathogens. 2024. PMID: 38787264 Free PMC article.
-
Efficacy of imipenem combined with dimercaptosuccinic acid in a murine sepsis model using Pseudomonas aeruginosa.Sci Rep. 2025 Aug 1;15(1):28047. doi: 10.1038/s41598-025-13554-7. Sci Rep. 2025. PMID: 40745035 Free PMC article.
-
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.Curr Issues Mol Biol. 2024 Dec 14;46(12):14132-14153. doi: 10.3390/cimb46120846. Curr Issues Mol Biol. 2024. PMID: 39727974 Free PMC article. Review.
-
Diagnostic algorithm for the detection of carbapenemases and extended-spectrum β-lactamases in carbapenem-resistant Pseudomonas aeruginosa.Microbiol Spectr. 2025 Jun 3;13(6):e0319624. doi: 10.1128/spectrum.03196-24. Epub 2025 Apr 16. Microbiol Spectr. 2025. PMID: 40237495 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous